Galena Biopharma, Inc. (GALE)

Analysts 2
Positive
0%
Median target $4 (534% upside)


    • 02/06/17
      FBR Capital Markets
      market perform
      $4
      "On January 31 Galena Biopharma announced that Mark W. Schwartz Ph.D. resigned as the company's..."
      View details
    • 02/02/17
      Maxim Group
      hold
      "From a clinical perspective we believe that NeuVax and GALE-401 have potential in breast cancer..."
      View details
    • 06/29/16
      Noble Financial
      hold
      $0.4
      "While the trials are ongoing/planned we await clarity on next steps for the NeuVax Phase 2..."
      View details
    • 06/29/16
      Raymond James
      market perform
    • 06/07/16
      Roth Capital
      buy
      $5
      "We see the positive correlations between vaccine [GALE-301 to prevent ovarian and endometrial..."
      View details
    • 01/22/16
      Oppenheimer
      outperform
      $4
    • 12/08/15
      Cantor Fitzgerald
      hold
      $2
      "With a modest cash payout from the lawsuit and the addition of $8 million from the recent..."
      View details
    • 08/10/15
      MLV & Co
      buy
      $5
      "Abstral revenues continue to be strong driven by increasing transaction prices. With the launch..."
      View details
    • 05/12/15
      Zacks
      buy
      $1.5
    • 03/06/15
      Needham & Company
      buy
      $4
      "Abstral put in its best quarter since launch with $3.2 million in revenue nearly double the $1.6..."
      View details
    • 03/06/15
      ING
      buy
    • 0% positive
      $4 Median

    Users who viewed GALE also viewed

    more

    Best rated stocks last 7 days

    more